AB Segulah increases stake in Advanced Oncotherapy plc

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 
 
 
 1. Identity of the issuer      Advanced Oncotherapy 
  or the underlying issuer               plc 
  of existing shares to which 
  voting rights are attached: 
  (ii) 
-----------------------------  --------------------- 
 
 
 2 Reason for the notification (please tick the 
  appropriate box or boxes): 
--------------------------------------------------- 
 An acquisition or disposal of voting rights      X 
----------------------------------------------- 
 An acquisition or disposal of qualifying 
  financial instruments which may result in 
  the acquisition of shares already issued 
  to which voting rights are attached 
----------------------------------------------- 
 An acquisition or disposal of instruments 
  with similar economic effect to qualifying 
  financial instruments 
----------------------------------------------- 
 An event changing the breakdown of voting 
  rights 
----------------------------------------------- 
 Other (please 
  specify): 
--------------------------------------------- 
 
 
 
 3. Full name of person(s)               AB Segulah 
  subject to the notification 
  obligation: (iii) 
----------------------------------  -------------------- 
 4. Full name of shareholder(s)      HSBC Global Custody 
  (if different from 3.):             Nominee (UK) 
  (iv) 
----------------------------------  -------------------- 
 5. Date of the transaction             20 March 2017 
  and date on which the threshold 
  is crossed or reached: (v) 
----------------------------------  -------------------- 
 6. Date on which issuer                20 March 2017 
  notified: 
----------------------------------  -------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached: (vi, vii)                         5% 
----------------------------------  -------------------- 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares (viii, ix) 
---------------------------------------------------------------------------------------------- 
 Class/type       Situation               Resulting situation after 
  of               previous                the triggering transaction 
  shares           to the triggering 
                   transaction 
  if possible 
  using 
  the ISIN 
  CODE 
---------------  ----------------------  ----------------------------------------------------- 
                  Number      Number      Number      Number of              % of voting 
                   of          of          of          voting                 rights (x) 
                   Shares      Voting      shares      rights 
                               Rights 
---------------  ----------  ----------  ----------  ---------------------  ------------------ 
                                          Direct      Direct      Indirect   Direct   Indirect 
                                                       (xi)        (xii) 
---------------  ----------  ----------  ----------  ----------  ---------  -------  --------- 
 Ordinary 
  Shares 
  GBP 0.25 
 
  GB00BD6SX109    3,505,451   3,505,451   3,680,451   3,680,451              5.06%
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked